Premera Blue Cross · Identified Jun 18, 2026Medium impact
Medical Policy and Coding Updates - October 2020
Effective October 1, 2020, Prescription Digital Therapeutics for Substance Use Disorder were considered investigational, and Intraoperative Neurophysiologic Monitoring added train of four monitoring as part of intraoperative monitoring that is not separately payable. Generic dimethyl fumarate was added as a first-line treatment for relapsing forms of multiple sclerosis, and Rituxan and Ruxience criteria for neuromyelitis optica spectrum disorder now require a confirmed diagnosis and no longer require a trial of a standard immunosuppressive drug. Coding updates added medical necessity and prior authorization review for HCPCS J9041, J9047, J0725, J3355, A9606, J9043, J3032, J3241, J9227 and J1632, required investigative review for Q4249, Q4250, Q4254, Q4255 and K1007, and made molecular genetic testing codes subject to AIM Specialty Health review with prior authorization.